. Author manuscript; available in PMC: 2017 Jan 1.

Published in final edited form as: Methods Mol Biol. 2016;1304:145–160. doi: 10.1007/7651_2014_88

Table 2.

Transgenic mouse models of experimental autoimmune encephalomyelitis

Background	TCR specificity	Cell-inducing disease	% of spontaneous disease	Age of onset (in weeks)	Clinical course
B10.PL/TCR tg B10.PL/TCR tg × RAG-1^−/−	MBP_Ac1–11 (32, 33)	CD4	14–44 % 100 %	5–20 6–20	Chronic/AM Chronic
C57BL/6 HLA-DR2/TCR tg DR2/TCR tg × RAG-2^−/−	huMBP_84–102 (34)	CD4	4 % 100 %	ND 7–15	Variable
C57BL/6 HLA-DR15/TCR tg DR15/TCR tg × RAG-2^−/−	huMBP_85–99 (35)	CD4	60 % 80–100 %	16–24 5–16	Chronic
SJL/J 5B6	PLP_139–151 (36)	CD4	40–60 %	6 and older	Chronic
C57BL/6 2D2	MOG_35–55 (37)	CD4	4–15 % 30–40 %	10–20 10–52	Chronic Optic neuritis
C57BL/6 2D2 × IgH_MOG	MOG_35–55 (38, 39)	CD4 B cells	50–60 %	4–10	Chronic with lesions only in spinal cord and optic nerve
SJL/J TCR1640	MOG_92–106 (40)	CD4 B cells	60–90 %	8–23	RR on female PP on male
C57BL/6 B7.2 expressed on microglia and T cells	ND (41, 42)	CD8	100 %	12–30	Chronic
C57BL/6 ODC-OVA × OT-I	OVA_257–264 (43)	CD8	90–100 %	1–3	Chronic/lethal
C57BL/6 HLA-A3/TCR tg	huPLP_45–53 (44)	CD8	4 %	ND	Motor deficit
NOD 1C6 × IgH_MOG	MOG_35–55 (45)	CD4 CD8 B cells	45–80 %	12–18	RR to chronic

AM acute monophasic, RR relapsing-remitting, PP primary progressive, tg transgenic, ODC oligodendrocytes, ND not defined